In androgen-independent C4-2 PCa cells, roscovitine (a known CDK inhibitor) treatment revoked responses to low androgen levels, emphasizing that increased CDK1 levels could sensitize CRPC cells to minimal androgen levels [39]. The gene discussed is CDK1; the disease is posterior cortical atrophy.